2026 Marketing Small Molecule Treatment 
Drug Target Review
JULY 4, 2023
These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.
Drug Target Review
JANUARY 4, 2024
This is in part due to a complex manufacturing process, which is harder to control than those used for other modalities (such as small molecules and monoclonal antibodies). By this point, we have undertaken a thorough analysis of what the market will look like at the anticipated product launch, including potential reimbursement models.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 6, 2022
Since 2017, a range of approvals by the FDA has resulted in cell therapies – in particular CAR-T-cell therapies – being used in the treatment of blood cancers. I would expect to see more data coming from the use of cell-based treatments for solid tumours such as breast, ovarian, pancreatic or colorectal cancer.
Drug Discovery World
JANUARY 24, 2024
Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic. PW: FIB992 is our lead compound.
The Pharma Data
DECEMBER 12, 2020
AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 5% have US Food and Drug Administration -approved treatments. 5% have US Food and Drug Administration -approved treatments.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. The prophylactic steroid treatment was also changed from 1 mg/kg to an intermediate dose of 2mg/kg. The most frequent treatment-emergent adverse events were nasopharyngitis and atopic dermatitis.
Drug Hunter
APRIL 24, 2023
The new laws include Medicare negotiation and includes a provision that disproportionately affects small molecules which have triggered reactions throughout the industry from the extreme of “this is the end of small molecule drug discovery as we know it” to “this may not cause permanent damage.”
Expert insights. Personalized for you.
145 
Let's personalize your content